David Barbie

David Barbie

Harvard University

H-index: 53

North America-United States

About David Barbie

David Barbie, With an exceptional h-index of 53 and a recent h-index of 44 (since 2020), a distinguished researcher at Harvard University, specializes in the field of Cancer research.

His recent articles reflect a diverse array of research interests and contributions to the field:

Combination STING agonist and NK cellular therapy in patient derived organotypic tumor spheroids

Multiomics analysis of impact of CD8+ and other cell populations in STING agonist treated ex vivo mesothelioma samples

Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects

Sting levels as a biomarker for cancer immunotherapy

TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity

Nonpathogenic E. coli engineered to surface display cytokines as a new platform for immunotherapy

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

An angiogenic target of immune exclusion with checkpoint blockade in melanoma

David Barbie Information

University

Position

Dana-Farber Cancer Institute

Citations(all)

18563

Citations(since 2020)

12704

Cited By

10333

hIndex(all)

53

hIndex(since 2020)

44

i10Index(all)

92

i10Index(since 2020)

85

Email

University Profile Page

Harvard University

Google Scholar

View Google Scholar Profile

David Barbie Skills & Research Interests

Cancer research

Top articles of David Barbie

Title

Journal

Author(s)

Publication Date

Combination STING agonist and NK cellular therapy in patient derived organotypic tumor spheroids

Cancer Research

Patrick H Lizotte

Elena Ivanova

Sung Park

Nathaniel Spicer

Sophie Kivlehan

...

2024/3/22

Multiomics analysis of impact of CD8+ and other cell populations in STING agonist treated ex vivo mesothelioma samples

Cancer Research

Elena Ivanova

Sung R Park

Ari P Zlota

Nathaniel Spicer

Minh Ha

...

2024/3/22

Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects

Molecular Cancer

Yufei Wang

Alicia Buck

Brandon Piel

Luann Zerefa

Nithyassree Murugan

...

2024/3/16

Sting levels as a biomarker for cancer immunotherapy

2024/1/16

TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity

Cancer Discovery

Tetsuo Tani

Haritha Mathsyaraja

Marco Campisi

Ze-Hua Li

Koji Haratani

...

2024/2/23

Nonpathogenic E. coli engineered to surface display cytokines as a new platform for immunotherapy

Rizwan Romee

Shaobo Yang

Michal Sheffer

Isabel Kaplan

Zongqi Wang

...

2024/3/22

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

Varadha Balaji Venkadakrishnan

Adam G Presser

Richa Singh

Matthew A Booker

Nicole A Traphagen

...

2024/2/8

An angiogenic target of immune exclusion with checkpoint blockade in melanoma

Cancer Research

Saba Tabasum

Dinesh Thapa

Anita Giobbie-Hurder

Jason L Weirather

Xinqi Wu

...

2023/4/4

Identification of synthetic lethal vulnerabilities in cancers with loss of function mutations in NOTCH

Cancer Research

Deli Hong

Matthew A Booker

Sidrah Anjum

Yixiang Li

Tran C Thai

...

2023/4/4

ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer

Nature Cancer

Ines Mota

Enrico Patrucco

Cristina Mastini

Navin R Mahadevan

Tran C Thai

...

2023/7

P2. 15-01 Priming SCLC Vasculature to Facilitate NK Cell Attack

Journal of Thoracic Oncology

M Campisi

C Stornante

M Tarannum

SR Park

P Lizotte

...

2023/11/1

Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers

Immunity

Olli Dufva

Sara Gandolfi

Jani Huuhtanen

Olga Dashevsky

Hanna Duàn

...

2023/12/12

Targeting TBK1 to overcome resistance to cancer immunotherapy

Nature

Yi Sun

Or-yam Revach

Seth Anderson

Emily A Kessler

Clara H Wolfe

...

2023/3/2

fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate on-target off-tumor side effects

Cancer Research

Yufei Wang

Alicia Buck

Gabriella Kastrunes

Rabia Abbas

Michael Lynch

...

2023/4/4

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma

Annals of Oncology

D Boiarsky

CA Lydon

ES Chambers

LM Sholl

M Nishino

...

2023/7/1

EDIL3 as an angiogenic target of immune exclusion following checkpoint blockade

Cancer Immunology Research

Saba Tabasum

Dinesh Thapa

Anita Giobbie-Hurder

Jason L Weirather

Marco Campisi

...

2023/11/1

Unraveling the Intricacies of CD73/Adenosine Signaling: The Pulmonary Immune and Stromal Microenvironment in Lung Cancer

Maria Saigí

Oscar Mesía-Carbonell

David A Barbie

Raquel Guillamat-Prats

2023/12/4

Methods for evaluating tumor cell spheroids using 3D microfluidic cell culture device

2019/4/18

Targeting TREX1 induces innate immune response in chemoresistant small cell lung cancer

Cancer Research

Takahiko Murayama

Navin R Mahadevan

Tetsuo Tani

Xueying Ma

Hideo Watanabe

...

2023/4/4

New strategy for promoting vascularization in tumor spheroids in a microfluidic assay

Advanced healthcare materials

Zhengpeng Wan

Marie A Floryan

Mark F Coughlin

Shun Zhang

Amy X Zhong

...

2023/6

See List of Professors in David Barbie University(Harvard University)